ijms-logo

Journal Browser

Journal Browser

Liposomes: The Smart and Targeted Drug Delivery in the Era of Nanomedicines

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Biochemistry".

Deadline for manuscript submissions: closed (31 March 2019) | Viewed by 20833

Special Issue Editors


E-Mail Website
Guest Editor
Women’s Health and Perinatology Research Group, Department of Clinical Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway
Interests: liposomes; drug delivery; reproductive health; inflammation; chronic diseases; antioxidative activity; oxidative stress biomarkers; functional foods; phytochemicals; natural medicines
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Drug Transport and Delivery Research Group, Department of Pharmacy, University of Tromsø, Universitetsveien 57, 9037 Tromsø, Norway
Interests: drug delivery; nanomedicine; liposomes; skin therapy; vaginal therapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The science of drug technology was born after the first and successful drug formulation of an “Aspirin tablet” designed in 1915. Within the course of 100 years, a vast number of pharmaceutical industries were created and developed all over the world generating the drug formulations destined for various routes of administration. For a chemical substance to induce a therapeutically beneficial effect and become a drug, it must reach its target site in the body at the required concentration remaining potent for a sufficient length of time. Therefore, for modern medicine, the drug carrier/vehicle plays an important role in solubilizing, stabilizing and targeting the drugs. In recent years, the concept of nanomedicines as smart drugs has immersed. Nanomedicine comprises nanoparticles able to carry the sufficient amount of drug molecules to the targeted cells. To develop a smart nanomedicine, the carrier surfaces are often modified to assure specific and controllable drug delivery. Such a smart drug delivery will reduce side effects and enhance drug efficacy.

Liposomes are the most commonly studied nanoparticles as drug nanocarriers. They can be prepared from different kinds of lipids and are regarded as safe nanocarriers. Drug-loaded liposomes can be converted into smart drugs by tailoring their surface properties. Therefore, the current Special Issue will explore the studies of liposomes as smart drug nanocarriers at various stages of design, development, characterization and in vitro/in vivo evaluation.

Prof. Dr. Purusotam Basnet
Prof. Dr. Natasa Skalko-Basnet
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • liposomes
  • nanomedicines
  • nanocarriers
  • smart drug
  • targeted drug delivery
  • topical delivery
  • skin delivery
  • vaginal drug delivery

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

18 pages, 5366 KiB  
Article
Targeting Ovarian Cancer Cells Overexpressing CD44 with Immunoliposomes Encapsulating Glycosylated Paclitaxel
by Apriliana Cahya Khayrani, Hafizah Mahmud, Aung Ko Ko Oo, Maram H. Zahra, Miharu Oze, Juan Du, Md Jahangir Alam, Said M. Afify, Hagar A. Abu Quora, Tsukasa Shigehiro, Anna Sanchez Calle, Nobuhiro Okada, Akimasa Seno, Koki Fujita, Hiroki Hamada, Yuhki Seno, Tadakatsu Mandai and Masaharu Seno
Int. J. Mol. Sci. 2019, 20(5), 1042; https://doi.org/10.3390/ijms20051042 - 27 Feb 2019
Cited by 37 | Viewed by 5477
Abstract
Paclitaxel (PTX) is one of the front-line drugs approved for the treatment of ovarian cancer. However, the application of PTX is limited due to the significant hydrophobicity and poor pharmacokinetics. We previously reported target-directed liposomes carrying tumor-selective conjugated antibody and encapsulated glycosylated PTX [...] Read more.
Paclitaxel (PTX) is one of the front-line drugs approved for the treatment of ovarian cancer. However, the application of PTX is limited due to the significant hydrophobicity and poor pharmacokinetics. We previously reported target-directed liposomes carrying tumor-selective conjugated antibody and encapsulated glycosylated PTX (gPTX-L) which successfully overcome the PTX limitation. The tubulin stabilizing activity of gPTX was equivalent to that of PTX while the cytotoxic activity of gPTX was reduced. In human ovarian cancer cell lines, SK-OV-3 and OVK18, the concentration at which cell growth was inhibited by 50% (IC50) for gPTX range from 15–20 nM, which was sensitive enough to address gPTX-L with tumor-selective antibody coupling for ovarian cancer therapy. The cell membrane receptor CD44 is associated with cancer progression and has been recognized as a cancer stem cell marker including ovarian cancer, becoming a suitable candidate to be targeted by gPTX-L therapy. In this study, gPTX-loading liposomes conjugated with anti-CD44 antibody (gPTX-IL) were assessed for the efficacy of targeting CD44-positive ovarian cancer cells. We successfully encapsulated gPTX into liposomes with the loading efficiency (LE) more than 80% in both of gPTX-L and gPTX-IL with a diameter of approximately 100 nm with efficacy of enhanced cytotoxicity in vitro and of convenient treatment in vivo. As the result, gPTX-IL efficiently suppressed tumor growth in vivo. Therefore gPTX-IL could be a promising formulation for effective ovarian cancer therapies. Full article
Show Figures

Figure 1

Review

Jump to: Research

27 pages, 3476 KiB  
Review
Soy Lecithin-Derived Liposomal Delivery Systems: Surface Modification and Current Applications
by Ngoc Thuy Trang Le, Van Du Cao, Thi Nhu Quynh Nguyen, Thi Thu Hong Le, Thach Thao Tran and Thai Thanh Hoang Thi
Int. J. Mol. Sci. 2019, 20(19), 4706; https://doi.org/10.3390/ijms20194706 - 23 Sep 2019
Cited by 98 | Viewed by 14762
Abstract
The development of natural phospholipids for nanostructured drug delivery systems has attracted much attention in the past decades. Lecithin that was derived from naturally occurring in soybeans (SL) has introduced some auspicious accomplishments to the drug carrying aspect, like effectual encapsulation, controlled release, [...] Read more.
The development of natural phospholipids for nanostructured drug delivery systems has attracted much attention in the past decades. Lecithin that was derived from naturally occurring in soybeans (SL) has introduced some auspicious accomplishments to the drug carrying aspect, like effectual encapsulation, controlled release, and successful delivery of the curative factors to intracellular regions in which they procure these properties from their flexible physicochemical and biophysical properties, such as large aqueous center and biocompatible lipid, self-assembly, tunable properties, and high loading capacity. Despite the almost perfect properties as a drug carrier, liposome is known to be quite quickly eliminated from the body systems. The surface modification of liposomes has been investigated in many studies to overcome this drawback. In this review, we intensively discussed the surface-modified liposomes that enhancing the targeting, cellular uptake, and therapeutic response. Moreover, the recent applications of soy lecithin-derived liposome, focusing on cancer treatment, brain targeting, and vaccinology, are also summarized. Full article
Show Figures

Figure 1

Back to TopTop